LUVOX CR
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Feb 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUVOX CR is an extended-release oral capsule formulation approved in 2008, containing fluvoxamine maleate, a selective serotonin reuptake inhibitor (SSRI). The mechanism of action involves inhibition of serotonin reuptake in the central nervous system. Indication and patient population details are not available in the provided data.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity, suggesting team focus shifting toward transition planning and generic containment strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring, typical for a product in LOE-approaching stage. Career roles are likely focused on transition planning and market stabilization rather than growth initiatives.
Brand ManagerProduct Manager
Worked on LUVOX CR at Jazz Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.